Literature DB >> 27221243

Interleukin 27 is up-regulated in patients with active inflammatory bowel disease.

Janette Furuzawa Carballeda1, Gabriela Fonseca Camarillo2, Jesús K Yamamoto-Furusho3.   

Abstract

The aim of the study was to characterize and quantify tissue gene and protein expression of IL-27 in ulcerative colitis (UC) and Crohn's disease (CD) patients. This is an observational and cross-sectional study. Fifty-four patients with IBD were studied: 27 active UC, 12 inactive UC, 10 active CD, and 5 inactive CD. All patients belonged to the Inflammatory Bowel Disease Clinic at the Instituto Nacional de Ciencias Médicas y Nutrición. We found that IL-27 gene expression was significantly higher in active UC versus inactive UC group (P = 0.015). The IL-27 mRNA expression was increased in patients with active CD compared with inactive CD disease (P = 0.035). The percentage of IL-27 immunoreactive cells was higher in active UC versus active CD patients and non-inflamed tissue controls. The IL-27 was significantly elevated in active UC and CD patients, and it was associated with disease severity.

Entities:  

Keywords:  Expression; IBD; Immunoregulatory; Inflammation; Interleukin

Mesh:

Substances:

Year:  2016        PMID: 27221243     DOI: 10.1007/s12026-016-8804-z

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  16 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

Review 2.  Molecular phylogeny within type I cytokines and their cognate receptors.

Authors:  Jean-Louis Boulay; John J O'Shea; William E Paul
Journal:  Immunity       Date:  2003-08       Impact factor: 31.745

Review 3.  New IL-6 (gp130) family cytokine members, CLC/NNT1/BSF3 and IL-27.

Authors:  Masaaki Murakami; Daisuke Kamimura; Toshio Hirano
Journal:  Growth Factors       Date:  2004-06       Impact factor: 2.511

4.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

Authors:  Ivan D Mascanfroni; Ada Yeste; Silvio M Vieira; Evan J Burns; Bonny Patel; Ido Sloma; Yan Wu; Lior Mayo; Rotem Ben-Hamo; Sol Efroni; Vijay K Kuchroo; Simon C Robson; Francisco J Quintana
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

5.  Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis.

Authors:  Jesús K Yamamoto-Furusho; Rosalinda Posadas-Sánchez; Edith Alvarez-León; Gilberto Vargas-Alarcón
Journal:  Immunol Lett       Date:  2016-02-18       Impact factor: 3.685

Review 6.  Interleukin-27 mediates inflammation during chronic disease.

Authors:  Christopher Wynick; Carlene Petes; Katrina Gee
Journal:  J Interferon Cytokine Res       Date:  2014-05-05       Impact factor: 2.607

Review 7.  Understanding the pro- and anti-inflammatory properties of IL-27.

Authors:  Alejandro V Villarino; Elaine Huang; Christopher A Hunter
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

8.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.

Authors:  L R Sutherland; F Martin; S Greer; M Robinson; N Greenberger; F Saibil; T Martin; J Sparr; E Prokipchuk; L Borgen
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

9.  Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.

Authors:  S A Riley; V Mani; M J Goodman; M E Herd; S Dutt; L A Turnberg
Journal:  Gastroenterology       Date:  1988-06       Impact factor: 22.682

10.  IL-27, targeting antigen-presenting cells, promotes Th17 differentiation and colitis in mice.

Authors:  A Visperas; J S Do; K Bulek; X Li; B Min
Journal:  Mucosal Immunol       Date:  2013-10-16       Impact factor: 7.313

View more
  7 in total

Review 1.  Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

Authors:  Ross John Porter; Caroline Andrews; Daniel Paul Brice; Scott Kenneth Durum; Mairi Hall McLean
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

Review 2.  Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Qingdong Guan; Jiguo Zhang
Journal:  Mediators Inflamm       Date:  2017-03-21       Impact factor: 4.711

3.  Evaluation of IL-12A, IL-12B, IL-23A and IL-27 mRNA expression level genes in peripheral mononuclear cells of inflammatory bowel disease patients in an Iranian population.

Authors:  Mohsen Norouzinia; Vahid Chaleshi; Samaneh Alinaghi; Saeedeh Sadat Beheshti Shirazi; Aliasghar Keramatinia; Mahyar Nourian
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018

4.  Association of single-nucleotide polymorphisms in the IL27 gene with autoimmune thyroid diseases.

Authors:  Weiwei He; Bin Wang; Kaida Mu; Jing Zhang; Yanping Yang; Wei Yao; Sheli Li; Jin-An Zhang
Journal:  Endocr Connect       Date:  2019-03-01       Impact factor: 3.335

5.  Faecalibacterium prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction.

Authors:  Joudy Alameddine; Emmanuelle Godefroy; Loukas Papargyris; Guillaume Sarrabayrouse; Julie Tabiasco; Chantal Bridonneau; Karina Yazdanbakhsh; Harry Sokol; Frédéric Altare; Francine Jotereau
Journal:  Front Immunol       Date:  2019-02-06       Impact factor: 7.561

6.  More fuel to the fire: some patients with non-celiac self-reported wheat sensitivity exhibit adaptive immunological responses in duodenal mucosa.

Authors:  Antonia Isabel Castillo-Rodal; Janette Furuzawa-Carballeda; Mario Peláez-Luna; José Castro-Gómez; Yolanda López-Vidal; Luis Uscanga
Journal:  BMC Gastroenterol       Date:  2020-12-09       Impact factor: 3.067

7.  Elevated Levels of IL-27 Are Associated with Disease Activity in Patients with Crohn's Disease.

Authors:  Xiufang Cui; Chunhua Jiao; Di Wang; Ziping Ye; Jingjing Ma; Nana Tang; Hongjie Zhang
Journal:  Mediators Inflamm       Date:  2021-10-26       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.